Benzinga | Nov 9, 2021 11:44AM EST

Immatics Reports Clinical Responses Across Multiple Solid Tumor Types In Ongoing ACTengine IMA203 Phase 1a Trial Targeting PRAME

* Dose escalation for cell therapy candidate ACTengine(r) IMA203 ongoing; dose level 3 completed at doses below 1 billion transduced cells

* Objective responses (RECIST 1.1) observed in 8/16 patients (50%) across multiple solid cancer types, with 8/13 responders (62%) treated at dose levels 2 and 3

* High T cell engraftment and persistence; clinical response associated with tumor infiltration

* Transient and manageable treatment-emergent adverse events; no higher-grade cytokine release syndrome or neurological toxicities observed

* IMA203 clinical data will be presented as late-breaking oral presentation at the SITC Annual Meeting on Saturday, November 13 at 12:00 pm EST